KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Revenue (2016 - 2025)

NovoCure's Revenue history spans 12 years, with the latest figure at $174.4 million for Q4 2025.

  • For Q4 2025, Revenue rose 8.11% year-over-year to $174.4 million; the TTM value through Dec 2025 reached $655.4 million, up 8.28%, while the annual FY2025 figure was $655.4 million, 8.28% up from the prior year.
  • Revenue for Q4 2025 was $174.4 million at NovoCure, up from $167.2 million in the prior quarter.
  • Across five years, Revenue topped out at $174.4 million in Q4 2025 and bottomed at $122.2 million in Q1 2023.
  • The 5-year median for Revenue is $136.1 million (2021), against an average of $142.1 million.
  • The largest annual shift saw Revenue skyrocketed 32.28% in 2021 before it dropped 11.17% in 2023.
  • A 5-year view of Revenue shows it stood at $133.2 million in 2021, then fell by 3.59% to $128.4 million in 2022, then rose by 4.17% to $133.8 million in 2023, then grew by 20.54% to $161.3 million in 2024, then increased by 8.11% to $174.4 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Revenue are $174.4 million (Q4 2025), $167.2 million (Q3 2025), and $158.8 million (Q2 2025).